Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
• Binding assay by FACS and cell based ELISA.
Fig. FACS analysis of CD40 Ligand on HEK293/Human CD40 Ligand Stable Cell Line.
FACS assay shows that CD40 Ligand Antibody can bind to HEK293/Human CD40 Ligand Stable Cell Line. HEK293/Human CD40 Ligand Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).
Please contact us if you are interested in related cell pool service.
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Dapirolizumab pegol | Anti-CD40L-Fab; Anti-CD40L-Fab-PEG; CDP-7657; CD40L - Fab; BIIB-133 | Phase 3 Clinical | Biogen Inc, Ucb | Autoimmune Diseases; Immune System Diseases; Connective Tissue Diseases; Lupus Erythematosus, Systemic; Skin and Connective Tissue Diseases | Details |
Dazodalibep | VIB-4920; MEDI-4920; HZN-4920(Horizon Therapeutics); UNII-HN5US76BWF; WHO-11399 | Phase 3 Clinical | Medimmune Llc, Horizon Therapeutics PLC | Rejection of renal transplantation; Sjogren's Syndrome; Arthritis, Rheumatoid; Lupus Nephritis; Rejection of organ transplantation; Sjogren-Larsson Syndrome | Details |
Frexalimab | INX-021; SAR-441344 | Phase 3 Clinical | Immunext Inc | Diabetes Mellitus, Type 1; Nephrosis; Sjogren's Syndrome; Multiple Sclerosis; Lupus Erythematosus, Systemic; Glomerulosclerosis, Focal Segmental; Sjogren-Larsson Syndrome; Glomerulonephritis | Details |
Anti-CD40L antibody (Bristol-Myers Squibb) | Phase 2 Clinical | Bristol-Myers Squibb Company | Immunologic Deficiency Syndromes | Details | |
AdCD40L | Phase 2 Clinical | Uppsala University | Urinary Bladder Neoplasms; Melanoma | Details | |
Tegoprubart | AT-1501 | Phase 2 Clinical | Als Therapy Development Institute | Rejection of renal transplantation; Diabetes Mellitus, Type 1; Glomerulonephritis, IGA; Amyotrophic Lateral Sclerosis; Diabetes Mellitus | Details |
Delolimogene mupadenorepvec | LOAd-703 | Phase 2 Clinical | Uppsala University, Lokon Pharma | Biliary Tract Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma | Details |
CD40 ligand expressing MSLN-CAR T cells | Phase 2 Clinical | Pla General Hospital | Solid tumours | Details | |
CD40L-augmented Tumor Infiltrating Lymphocytes (H Lee Moffitt Cancer Center & Research Institute) | Phase 2 Clinical | H Lee Moffitt Cancer Center & Research Institute | Carcinoma, Non-Small-Cell Lung | Details | |
Letolizumab | BMS-986004; BMS2h-572-633-CT-L2 | Phase 1 Clinical | Bristol-Myers Squibb Company | Purpura, Thrombocytopenic, Idiopathic; Graft vs Host Disease | Details |
TNX-1500 | TNX-1500 | Phase 1 Clinical | Tonix Pharmaceuticals Holding Corp | Autoimmune Diseases; Rejection of organ transplantation; Autoimmune Diseases of the Nervous System | Details |
MEM-288 | MEM-288 | Phase 1 Clinical | Memgen | Head and Neck Neoplasms; Solid tumours; Carcinoma, Merkel Cell; Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
IBI355 | IBI-355 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Sjogren's Syndrome; Lupus Erythematosus, Systemic | Details |
APB-A1 | APB-A1; Lu-AG22515 | Phase 1 Clinical | AprilBio Co Ltd | Graves Ophthalmopathy; Neuromyelitis Optica | Details |
This web search service is supported by Google Inc.